

Momelotinib for treating myelofibrosis-related splenomegaly or symptoms

Information for the public
Published: 20 March 2024

www.nice.org.uk

Momelotinib (Omirra) is available on the NHS. It is a possible treatment for myelofibrosis-related splenomegaly or symptoms in adults with moderate to severe anaemia if:

- they have not had a JAK inhibitor or have had ruxolitinib, and
- they have intermediate-2 or high-risk myelofibrosis.

If you are not eligible for momelotinib but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

These organisations can give you advice and support:

- [Leukaemia care](#), 08088 010 444
- [MPN Voice](#), info@mpnvoice.org.uk

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5845-0